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Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) and can be aggravated by comorbid diseases. In administering
COVID-19 therapy, we need to consider potential drug-drug interactions (pDDIs) with comorbid
drugs. Most patients with comorbid diseases get polypharmacy, therefore the risk of pDDIs
increases. Potential drug-drug interactions can cause unwanted effects such as toxicity to death.
There is no on-label therapy for COVID-19 but FDA has Emergency Use Authorization (EUA)
for hydroxychloroquine, chloroquine, azithromycin, remdesivir, ritonavir, and lopinavir. Some
COVID-19 treatment potential drug-drug interactions have a level of severity C and D, so there is a
high need for close monitoring during drug administration or modification therapy.
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INTRODUCTION
Corona Virus Disease-2019 (COVID-19) is a new
disease caused by the coronavirus attacking the
respiratory tract and was first reported in Wuhan,
China on December 31, 2019. On January 30, 2020,
the Public Health Emergency of International Concern
announced that it was an international pandemic (World
Health Organization, 2020). Not much clinical data
and management therapy is known considering this is
a new disease. There is no on-label therapy and vaccine
for COVID-19. The number of COVID-19 patients is
increasing from day to day throughout the world (John
Hopkins University, 2020).
There are asymptomatic to severe symptoms shown by
patient COVID-19. Symptoms are felt 2-14 days after
the patient is exposed. Symptoms reported include
fever (83-99%), cough (59-82%), weakness (44-70%),
anorexia (40-84%), difficulty breathing (31-40%),
phlegm (28-33%), and myalgia (11-35%). Based on
available data, the elderly and people with comorbid
diseases have a greater risk of COVID-19 (Centers for
Disease Control and Prevention, 2020).
Of 216 countries, 4.7 million patients were confirmed
COVID-19, and 0.4% of patients from Indonesia
(Ministry of Health, Republic of Indonesia, 2020). The
highest number of patients by age was among those from
the age group of 15-44 years (55.1%) and >65 years
(41.9%). COVID-19 patients with high severity in the
15-49 years old group (41.15%), 50-64 years (31.3%),
and >65 years (27.0%) (Guan et al., 2020). Case

Fatality Rate (CFR) of COVID-19 critical patients had
comorbidities including cardiovascular disease 10.5%,
diabetes mellitus 7.3%, chronic respiratory disease
6.3%, hypertension 6%, and oncological disease 5.6%
(Wu & McGoogan, 2020).
Until now there has been no drug approved by the
FDA for COVID-19 therapy. Hydroxychloroquine and
chloroquine sulfate already has an Emergency Use
Authorization (EUA) from FDA so that it can be given to
adult COVID-19 patients weighing more than 50 kg who
are hospitalized (Food and Drug Administration, 2020).
This drug is also currently in clinical trials for COVID-19
therapy called Solidarity Trial held by WHO (WHO,
2020). Guidelines for COVID-19 therapy based on The
Indonesian Society of Respirology include chloroquine,
hydroxychloroquine,
azithromycin,
oseltamivir,
ritonavir, lopinavir, and remdesivir (Indonesian Society
of Respirology, 2020).
The selection of COVID-19 therapy needs to consider
the interaction of COVID-19 drugs with the treatment
of comorbid diseases. The majority of patients with
comorbidities get polypharmacy, thereby will increasing
the risk of potential Drug-Drug Interactions (pDDIs).
Therefore, this review is expected to provide information
on clinically significant drug interactions to be a
reference in the administration of COVID-19 therapy.
DRUG INTERACTIONS
Drugs administered with other drugs, herbs, food, drinks,
or chemicals lead to drug interactions. Drug interactions
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can provide advantages by increasing the effectiveness
of drugs, but also provide disadvantages such as
reducing the effectiveness of drugs, side effects, and
even toxicity. Drug interactions based on the mechanism
are divided into pharmaceutics, pharmacokinetics,
and pharmacodynamics (Baxter & Stockley, 2010).
Based on the occurrence, it is divided into actual and
potential drug interactions, while based on the severity
divided into minor (some references mention A and
B), moderate (C), major (D), and contraindications (X)
(Baxter & Stockley, 2010; Lacy et al., 2010). In the
minor category, drug interactions do not have clinically
significant effects. The major category requires close
monitoring during therapy, while the significant category
is recommended for modification with other therapies.
The contraindication category indicates that these drugs
should not be given combination because the risk is
greater than benefits (Lacy et al., 2010). The profile of
pDDIs COVID-19 is shown in Table 1.
CHLOROQUINE PHOSPHATE
Chloroquine phosphate is an antimalarial that is
metabolized and affecting the metabolism of other drugs
used together and metabolized in the CYP2D6 and
CYP3A4.
Magnesium trisilicate which is an antacid has
pharmacokinetic interactions thereby reducing the
absorption of chloroquine and hydroxychloroquine.
The dissolution of chloroquine tablets was also delayed
by magnesium trisilicate. The use of chloroquine and
antacids need to be given in 2-4 hours (Centers for
Disease Control and Prevention, 2019). Cimetidine 400
mg for 4 days reduces the metabolism and clearance
of chloroquine 600 mg. This increases the half-life of
cimetidine to 3.1-4.6 days in 10 patients. The use of this
combination is recommended to be avoided and replaced
with ranitidine that does not interact with chloroquine
and hydroxychloroquine (Ette,1987; Baxter & Stockley,
2010). Some chloroquine phosphate interactions that are
included in category C are bisoprolol, digoxin, codeine,
deferasirox, and tramadol. The interaction mechanism
is by inhibiting metabolism and decreasing the effect
of codeine and tramadol. Chloroquine is a CYP2D6
inhibitor that inhibits the metabolism of tamoxifen into
an active form of metabolite. This drug interaction is
included in category D, so it needs to be considered for
modification of therapy. The interaction of chloroquine
with mefloquine which is also an antimalarial can increase
mefloquine levels, causing the risk of prolongation of
QTc and convulsions (Lacy et al., 2010).
HYDROXYCHLOROQUINE
Hydroxychloroquine in the same therapeutic class as
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chloroquine, so some chloroquine interactions also
occur in hydroxychloroquine. There are 2 case reports
related to the use of hydroxychloroquine with rifampicin.
Rifampicin is an enzyme inducer, thus increasing
the metabolism of hydroxychloroquine which causes
increasing hydroxychloroquine clearance and the severity
of lupus in both patients. Although there were only 2 case
reports on this interaction, the effect was significant. In
the administration of the two drugs, it is recommended
to increase the dose of hydroxychloroquine and monitor
closely (Harvey et al., 1995; Ahmad et al., 2012).
Hydroxychloroquine decreases lysosomal insulin-insulin
receptor degradation and increases insulin sensitivity.
Several studies have shown improvements in fat profile
and blood sugar levels. Blood sugar monitoring is still
being done to prevent hypoglycemia (Seikhbahaie, 2016;
Khunti, 2020; Wondafrash et al., 2020). Interacting
with beta-blockers except for atenolol, cartenolol,
and nadolol with moderate severity, so it is necessary
to monitor blood pressure closely during therapy.
Interaction with digoxin requires consideration of the
selection of other drugs because it can increase digoxin
levels, thereby increasing the risk of digoxin toxicity.
The use of hydroxychloroquine with mefloquine is not
recommended because it can increase the risk of QTc
prolongation and seizures. If it must be used together,
mefloquine is given 12 hours after the last dose of
hydroxychloroquine (Lacy et al., 2010).
AZITHROMYCIN
Azithromycin is a macrolide class of antibiotics that
is indicated for pneumonia. Azithromycin increases
cardiac glycoside level, so it is not recommended to
be used together (Bizjak, 1997; Gomes, 2009). In line
with digoxin, QTc prolongation occurs in patients when
azithromycin is used together with amiodarone. It is
recommended to replace it with another drug (Samarendra
et al., 2001; Baxter & Stockley, 2010). Azithromycin can
reduce the metabolism of cyclosporine and warfarin so
that it is necessary to monitor during therapy. Tacrolimus
level increase when used together with azithromycin,
monitoring needs to be done (Mori et al., 2005).
LOPINAVIR/ RITONAVIR
Lopinavir and ritonavir are anti-HIV protease inhibitors.
This class has the most pDDIs compared to other
COVID-19 therapies. Close monitoring should be
carried out if lopinavir/ritonavir is used together with
antacids, digoxin, theophylline, tramadol, and warfarin.
A female patient experienced vomiting and was taken
to the emergency room after receiving ritonavir therapy
for 2 days & the patient took 0.25 mg digoxin a day
for therapy after heart surgery (Phillips et al., 2003;
Hughes et al., 2007). Ritonavir is an enzyme inhibitor
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Table 1. Profile of pDDIs in COVID-19 and Its Comorbid Therapy
COVID-19 Drug

Other Drug

Severity

Mechanism

Effect

Recommendation

Chloroquine

Antacids
Cimetidine
Bisoprolol
Digoxin
Mefloquine
Rifampicin
Glimepiride
Metformin
Bisoprolol
Digoxin
Mefloquine
Digoxin
Amiodarone
Warfarin
Tacrolimus
Cyclosporine
Digoxin
Theophylline
Warfarin
Nifedipine
Amlodipine
Nicardipine
Statins
Phenytoin
Rifampicin
Amiodarone
Influenza vaccine
Probenecid

Moderate
Major
Moderate
Moderate
Contraindication
Major
Moderate
Moderate
Moderate
Moderate
Contraindication
Major
Contraindication
Moderate
Moderate
Moderate
Moderate
Moderate
Moderate
Major
Major
Major
Moderate
Major
Contraindication
Contraindication
Contraindication
Moderate

PK
PK
PK
PK
PK
PK
PD
PD
PK
PK
PK
PK
PK
PK
PK
PK
PK
PK
PK
PK
PK
PK
PK
PK
PK
PK
PK
PK

Reduced absorption of chloroquine
Prolonged half-life chloroquine
Increased bisoprolol level
Increased digoxin level
Prologed QTc
Reduced hydroxychloroquine level
Improved glycemic control
Improved glycemic control
Increased bisoprolol level
Increased digoxin level
Prolonged QTc
Increased digoxin level
Prolonged QTc
Increased warfarin level
Increased tacrolimus level
Increased cyclosporine level
Increased digoxin level
Increased theophylline level
Increased warfarin level
Increased calcium channel blocker
(CCB) level

4 hours apart
Use ranitidine
Monitor closely
Monitor closely
Avoid combination
Increase dose of hydroxychloroquine & monitor closely
Monitor closely
Monitor closely
Monitor closely
Monitor closely
Avoid combination
Use other class
Avoid combination
Monitor closely
Monitor closely
Monitor closely
Monitor closely
Monitor closely
Monitor closely
Use with caution

Increased creatinine kinase
Decreased lopinavir/ritonavir level
Decreased lopinavir/ritonavir level
Prolonged QTc
Decreased vaccine effect
Increased oseltamivir level

Use minimal dose of statins or Pivastatin
Use gabapentin, lamotrigine
Avoid combination
Avoid combination
2 weeks after vaccine administration
Monitor closely

Hydroxychloroquine

Azithromycin

Lopinavir/
Ritonavir

Oseltamivir

*PK= pharmacokinetic; PD= pharmacodynamic
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that can increase digoxin levels. Digoxin has a narrow
therapeutic index so that even a little addition can
reach toxic levels (Ding et al., 2004). Category D drug
interactions are quite large with lopinavir/ritonavir.
Drugs that interact are drugs that are routinely taken
for comorbid therapy. Non-dihydropyridine Calcium
Channel Blocker (CCB) levels will increase because
protease inhibitors inhibit their metabolism. A 47-yearold male patient taking ritonavir/lopinavir after several
years received nifedipine, furosemide, and doxazosin.
The next day, the patient developed hypotension,
oliguria, and generalized edema (Baeza et al., 2007).
Increased levels of HMG-CoA reductase inhibitors also
occur when used together with lopinavir/ritonavir, so it
is recommended to modify drugs or use minimal doses
and monitor the occurrence of rhabdomyolysis (Piliero,
2002; UCSF, 2019). An increase in creatinine kinase 17
times above normal is reported in 1 healthy subject out
of the 20 subjects observed (Kiser et al., 2008). Protease
inhibitors increase ketoconazole level so the maximum
dose of ketoconazole is 200 mg/ day if given together
with ritonavir. Effects phenytoin and birth control pills
reduce the level of lopinavir/ritonavir. We need to be
replaced with other drugs for effective therapy (Lim et
al., 2004; UCSF, 2019).
The use of protease inhibitors and rifampicin is not
recommended because rifampicin can reduce levels of
protease inhibitors. The dose adjustment is shown a high
incidence of hepatotoxicity. Vincristine and vinblastine
toxicity can occur when used together with protease
inhibitors, so it is recommended to replace the therapy.
Protease inhibitors should not be used in conjunction
with amiodarone because it can reduce amiodarone
metabolism and all protease inhibitor probably have the
same interaction mechanism (Baxter & Stockley, 2010;
Lacy et al., 2010).
OSELTAMIVIR
Oseltamivir is antiviral influenza that inhibits
neuraminidase. Oseltamivir inhibits the replication of the
influenza vaccine so that the administration of oseltamivir
is recommended up to 2 weeks after influenza vaccine
administration, while the influenza vaccine can be given
after 48 hours of oseltamivir is stopped. Oseltamivir
levels increase in patients taking probenecid together
with oseltamivir. This is still safe because oseltamivir
has a wide therapeutic index so that it can increase the
effectiveness of oseltamivir (Baxter & Stockley, 2010).
REMDESIVIR
There is no data on remdesivir drug interactions. This is
likely due to no interactions or data related to remdesivir
drug interactions. At present remdesivir has EUA from
E-ISSN 2477-0612
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the FDA for COVID-19 therapy. This decision was
made based on clinical trials that have been carried
out together with NIH showing positive and significant
results. Remdesivir can be given to COVID-19 pediatric
and adult patients who have low oxygen levels or need a
ventilator (Food and Drug Administration, 2020).
CONCLUSION
In providing effective COVID -19 therapy, drug-drug
interactions should not be ignored. COVID-19 drugs
have quite a lot of pDDIs through the mechanism of
absorption, distribution, metabolism, and elimination.
Pharmacists and the medical team that treats patients
are responsible for preventing the effects of unwanted
drug-drug interactions. Therefore, the quality of life of
COVID-19 patients with comorbidities will improve.
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